Emergency department–initiated buprenorphine for opioid use disorder
About The Study: No difference was detected in opioid use disorder treatment engagement on day 7 between the 7-day extended-release and sublingual buprenorphine groups. Both buprenorphine formulations were well tolerated; precipitated withdrawal was rare despite a high prevalence of fentanyl. Corresponding Author: To contact the corresponding author, Gail D’Onofrio, MD, email gail.dononfrio@yale.edu. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jama.2025.27019) Editor’s Note: Please see the article for additional information, ...
Read the release